Lactoferrin or Progesterone for Prevention of Preterm Delivery
Status:
Unknown status
Trial end date:
2020-12-01
Target enrollment:
Participant gender:
Summary
Primary endpoint will be evaluate the effectiveness of vaginal lactoferrin in the reduction
of the 30% of preterm deliveries versus the use of progesterone, in specific selected
patients, with consequent improvement in neonatal outcome.
Secondary endpoint will be compare antibacterial and anti-inflammatory activity of
lactoferrin by evaluation of systemic biochemical and urinary markers.